Biotech News

TG Therapeutics Ranked Number 5 Fastest-Growing Company in North America on the 2026 Deloitte Technology Fast 500™

TG Therapeutics (TGTX)TG TherapeuticsCompany update

Third Year in a Row, Named as One of the Fastest-Growing Companies in North America NEW YORK --(BUSINESS WIRE)--Nov. 18, 2026-- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number 5 on the Deloitte Technology Fast 500 ™, a ranking of the 500 fastest-growing technology, media,

Related news

TG Therapeutics

B-Cell-Directed Therapies TG Therapeutics develops and commercializes therapies targeting B cells in multiple sclerosis and other autoimmune diseases. Its portfolio combines an approved anti-CD20 antibody with alternative formulations and an allogeneic cell-therapy program. BRIUMVI BRIUMVI, or ublituximab, is a glycoengineered CD20...

Recent company news

Stock data

Close
64.88 USD
Market cap
5.61B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States